Featured

Pulmonary Hypertension

Supplementing Pulmonary Arterial Hypertension Therapy With Nutritional Changes

Supplementing Pulmonary Arterial Hypertension Therapy With Nutritional Changes

Current research suggests patients with pulmonary arterial hypertension may benefit from iron and vitamin D supplementation.

Pulmonary Hypertension Improving Risk Stratification, Diagnostic Accuracy in PAH With Cardiopulmonary Exercise Testing

Improving Risk Stratification, Diagnostic Accuracy in PAH With Cardiopulmonary Exercise Testing

Cardiopulmonary exercise testing can be an important diagnostic and prognostic tool in pulmonary arterial hypertension.

Pulmonary Hypertension Improved Pulmonary Arterial Hypertension Risk Prediction Tools Needed

Improved Pulmonary Arterial Hypertension Risk Prediction Tools Needed

The use of a risk calculator aimed at achieving a low-risk profile in PAH trials is discussed.

Pulmonary Hypertension PAH-Associated Connective Tissue Diseases: A Case for Separating SSc, SLE

PAH-Associated Connective Tissue Diseases: A Case for Separating SSc, SLE

Recent evidence suggests that systemic sclerosis and systemic lupus erythematosus in pulmonary arterial hypertension should be considered separate diseases.

Pulmonary Hypertension Lung Transplantation for Pulmonary Arterial Hypertension: Overview and Bridging Therapies

Lung Transplantation for Pulmonary Arterial Hypertension: Overview and Bridging Therapies

Lung transplantation may be an option in patients with severe pulmonary arterial hypertension who do not respond well to medical therapy.

Pulmonary Hypertension Pulmonary Arterial Hypertension: Using Biomarkers to Assess Treatment Response

Pulmonary Arterial Hypertension: Using Biomarkers to Assess Treatment Response

Using biomarkers in pulmonary arterial hypertension may be a less invasive strategy for assessing response to treatment.

Pulmonary Arterial Hypertension-PAH Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: Definitions and Treatments

Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: Definitions and Treatments

Pulmonary arterial hypertension is becoming a major cause of death in patients with systemic sclerosis.

Pulmonary Hypertension Pulmonary Arterial Hypertension: Mechanisms of Exercise Intolerance

Pulmonary Arterial Hypertension: Mechanisms of Exercise Intolerance

Respiratory muscle dysfunction, iron deficiency, and skeletal muscle dysfunction have been implicated as mechanisms for exercise intolerance in pulmonary arterial hypertension.

Pulmonary Hypertension Pulmonary Arterial Hypertension: Future Treatment May Depend on Race and Ethnicity

Pulmonary Arterial Hypertension: Future Treatment May Depend on Race and Ethnicity

Pulmonary arterial hypertension tends to vary in presentation in patients of different races and ethnicities.

Pulmonary Hypertension Managing Pulmonary Hypertension in Preterm Neonates: Updates in an Emerging Field

Managing Pulmonary Hypertension in Preterm Neonates: Updates in an Emerging Field

Prenatal factors such as intrauterine growth retardation, infection, and placental inflammation can affect lung development in neonates.

Pulmonary Hypertension Pulmonary Thromboendarterectomy Curative for CTEPH Linked to APS

Pulmonary Thromboendarterectomy Curative for CTEPH Linked to APS

Pulmonary thromboendarterectomy appears to be a curative resolution in patients with antiphospholipid syndrome related to chronic thromboembolic pulmonary hypertension.

Pulmonary Hypertension Exercise Oxygen Desaturation, Pulmonary Function Predict Outcomes in SSc-PH

Exercise Oxygen Desaturation, Pulmonary Function Predict Outcomes in SSc-PH

Factors associated with a higher risk for mortality included male sex, exercise desaturation, and diffusing capacity of the lungs for carbon monoxide <50%.

Pulmonary Hypertension Pulmonary Vascular Disease and Late Respiratory Disease Link in Preterm Infants

Pulmonary Vascular Disease and Late Respiratory Disease Link in Preterm Infants

Preterm infants who need mechanical ventilation at day 7 and early echocardiographic evidence of pulmonary vascular disease are strong risk factors for late respiratory disease.

Pulmonary Hypertension Follow-Up Hemodynamics in Systemic Sclerosis-PAH Associated With 1-Year Outcomes

Follow-Up Hemodynamics in Systemic Sclerosis-PAH Associated With 1-Year Outcomes

At follow-up, the 6-minute walk distance, cardiac index, stroke volume index, and other hemodynamic variables were independently associated with transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension.

CHEST 2018 RV Hemodynamics Improved With Riociguat in Pulmonary Arterial Hypertension

RV Hemodynamics Improved With Riociguat in Pulmonary Arterial Hypertension

Riociguat was associated with increases in right ventricular work, right ventricular work index, stroke volume index, stroke volume index, and cardiac efficiency in patients with pulmonary arterial hypertension.

CHEST 2018 High Treprostinil Doses Delay PAH-Related and All-Cause Hospitalizations

High Treprostinil Doses Delay PAH-Related and All-Cause Hospitalizations

Higher doses of treprostinil significantly delayed time to first pulmonary arterial hypertension-related or all-cause hospitalization.

CHEST 2018 Macitentan Tolerated in Portopulmonary Hypertension

Macitentan Tolerated in Portopulmonary Hypertension

Recent data suggest that the endothelin receptor antagonist macitentan can be used to target the endothelin pathway in patients with portopulmonary hypertension.

Pulmonary Hypertension Pulmonary Artery Wedge Pressure and LVEDP Variance in Pulmonary Hypertension

Pulmonary Artery Wedge Pressure and LVEDP Variance in Pulmonary Hypertension

In some patients at risk for pulmonary hypertension, left ventricular end diastolic pressure measurement with standard right heart catheterization should be used.

Pulmonary Hypertension Generic Version of Adcirca Now Available for Pulmonary Arterial Hypertension

Generic Version of Adcirca Now Available for Pulmonary Arterial Hypertension

Tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, is indicated to treat pulmonary arterial hypertension to improve exercise ability.

Pulmonary Hypertension Orenitram Decreased Risk of Morbidity/Mortality Event in PAH Trial

Orenitram Decreased Risk of Morbidity/Mortality Event in PAH Trial

United Therapeutics announced that the Phase 3 trial of Orenitram for PAH has met its primary endpoint of delayed time to first clinical worsening event.

Sign Up for Free e-newsletters